Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF.

N Engl J Med. 2014 Aug 21;371(8):699-710. doi: 10.1056/NEJMoa1401731.

2.

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC.

Cochrane Database Syst Rev. 2017 Jan 17;1:CD003146. doi: 10.1002/14651858.CD003146.pub3. Review.

PMID:
28094851
3.

Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR.

Cochrane Database Syst Rev. 2017 May 13;5:CD012389. doi: 10.1002/14651858.CD012389.pub2. Review.

4.

Blood transfusion therapy is feasible in a clinical trial setting in children with sickle cell disease and silent cerebral infarcts.

King AA, Noetzel M, White DA, McKinstry RC, Debaun MR.

Pediatr Blood Cancer. 2008 Mar;50(3):599-602.

PMID:
17985350
5.

Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease.

Hulbert ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA, Sarnaik SA, Woods GM, Casella JF, Inusa B, Howard J, Kirkham FJ, Anie KA, Mullin JE, Ichord R, Noetzel M, Yan Y, Rodeghier M, Debaun MR.

Blood. 2011 Jan 20;117(3):772-9. doi: 10.1182/blood-2010-01-261123. Epub 2010 Oct 12.

6.

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D.

N Engl J Med. 1998 Jul 2;339(1):5-11.

7.

Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity.

Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG, Bello J, Zimmerman RA, Adams RJ, Brambilla D; STOP Trial.

Arch Neurol. 2001 Dec;58(12):2017-21.

PMID:
11735775
8.

Stroke prevention trial in sickle cell anemia.

Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, Roach S, Abboud M, Berman B, Driscoll C, Files B, Hsu L, Hurlet A, Miller S, Olivieri N, Pegelow C, Scher C, Vichinsky E, Wang W, Woods G, Kutlar A, Wright E, Hagner S, Tighe F, Waclawiw MA, et al.

Control Clin Trials. 1998 Feb;19(1):110-29.

PMID:
9492971
9.

Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease.

Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR.

Blood. 2002 Apr 15;99(8):3014-8.

10.

Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy.

Hall EM, Leonard J, Smith JL, Guilliams KP, Binkley M, Fallon RJ, Hulbert ML.

Pediatr Blood Cancer. 2016 Aug;63(8):1431-7. doi: 10.1002/pbc.26022. Epub 2016 Apr 22.

11.

Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction.

Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, Kwiatkowski JL, Roach ES, Kirkham FJ, Casella JF, DeBaun MR.

J Pediatr. 2014 May;164(5):1175-1180.e1. doi: 10.1016/j.jpeds.2014.01.001. Epub 2014 Feb 13.

12.

Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure.

DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Noetzel MJ, Ichord RN, Casella JF.

Blood. 2012 Apr 19;119(16):3684-90. doi: 10.1182/blood-2011-05-349621. Epub 2011 Nov 17.

13.

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Wang WC, Dwan K.

Cochrane Database Syst Rev. 2013 Nov 14;(11):CD003146. doi: 10.1002/14651858.CD003146.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Jan 17;1:CD003146.

14.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Lancet. 2016 Feb 13;387(10019):661-70. doi: 10.1016/S0140-6736(15)01041-7. Epub 2015 Dec 6.

15.

Design of the silent cerebral infarct transfusion (SIT) trial.

Casella JF, King AA, Barton B, White DA, Noetzel MJ, Ichord RN, Terrill C, Hirtz D, McKinstry RC, Strouse JJ, Howard TH, Coates TD, Minniti CP, Campbell AD, Vendt BA, Lehmann H, Debaun MR.

Pediatr Hematol Oncol. 2010 Mar;27(2):69-89. doi: 10.3109/08880010903360367.

16.

Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.

Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators.

N Engl J Med. 2005 Dec 29;353(26):2769-78.

17.

Sickle cell anemia: intracranial stenosis and silent cerebral infarcts in children with low risk of stroke.

Arkuszewski M, Krejza J, Chen R, Ichord R, Kwiatkowski JL, Bilello M, Zimmerman R, Ohene-Frempong K, Melhem ER.

Adv Med Sci. 2014 Mar;59(1):108-13. doi: 10.1016/j.advms.2013.09.001. Epub 2014 Mar 27.

PMID:
24797985
18.

Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy.

Beverung LM, Strouse JJ, Hulbert ML, Neville K, Liem RI, Inusa B, Fuh B, King A, Meier ER, Casella J, DeBaun MR, Panepinto JA; SIT trial investigators.

Am J Hematol. 2015 Feb;90(2):139-43. doi: 10.1002/ajh.23877.

19.

Silent Cerebral Infarct Transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain.

Vendt BA, McKinstry RC, Ball WS, Kraut MA, Prior FW, Barton B, Casella JF, DeBaun MR.

J Digit Imaging. 2009 Jun;22(3):326-43. doi: 10.1007/s10278-008-9114-3. Epub 2008 Apr 9.

20.

Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia.

DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ.

Blood. 2012 May 17;119(20):4587-96. doi: 10.1182/blood-2011-02-272682. Epub 2012 Feb 21. Review.

Supplemental Content

Support Center